Assessment of vaccine candidates for persons aged 50 and older: A review

BMC Geriatrics

Volumn 13, Issue 1, 2013, Pages

  Eilers, Renske ^a,b   Krabbe, Paul F M ^a   Van Essen, Ted G A ^c   Suijkerbuijk, Anita ^b   Van Lier, Alies ^b   De Melker, Hester E ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Hepatitis A; Herpes zoster; Older persons; Pertussis; Pneumococcal disease; Vaccination; Vaccines

Indexed keywords

VACCINE;

AGE; AGED; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH STATUS; HUMAN; MALE; MIDDLE AGED; MORTALITY; PROCEDURES; TREATMENT OUTCOME; VACCINATION; VERY ELDERLY; METHODOLOGY; REVIEW;

AGE FACTORS; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VACCINATION; VACCINES;

EID: 84876117065     PISSN: None     EISSN: 14712318     Source Type: Journal    
DOI: 10.1186/1471-2318-13-32     Document Type: Article

References (80)

1. Eurostat, Mortality and life expectancy statistics Belgium: European Commission 2011
2. Eurostat, Healthy life years statistics Belgium: European Commission 2011
3. European Commission, Europe in figures: Eurostat yearbook 2010 Luxemburg: European Union 2010
4. Associations between cytomegalovirus infection and functional impairment and frailty in the BELFRAIL Cohort. Mathei C, Vaes B, Wallemacq P, Degryse J, J Am Geriatr Soc 2011 59 12 2201 2208 10.1111/j.1532-5415.2011.03719.x 22092044
5. Epidemiology and unique aspects of aging and infectious diseases. Yoshikawa TT, Clin Infect Dis 2000 30 6 931 933 10.1086/313792 10880303 (Pubitemid 32250334)
6. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M, et al. Mech Ageing Dev 2007 128 1 92 105 10.1016/j.mad.2006.11.016 17116321 (Pubitemid 46073065)
7. World Health Organisation (WHO), WHO Vaccine Preventable Diseases Monitoring System Geneva: World Health Organisation 2011 27-09-2011
8. Coalition of advocates to vaccinate of Western European citizens aged 60 years and older. Michel JP, Chidiac C, Grubeck-Loebenstein B, Johnson RW, Lambert PH, Maggi S, Moulias R, Nicholson K, Werner H, Aging Clin Exp Res 2009 21 3 254 257 19571651
9. Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. Kimman TG, Boot HJ, Berbers GA, Vermeer-de Bondt PE, Ardine de Wit G, de Melker HE, Vaccine 2006 24 22 4769 4778 10.1016/j.vaccine.2006.03.022 16616803 (Pubitemid 43776793)
10. National Health Council the Netherlands, The future of the national immunisation program: towards a program for all age groups The Hague: National Health Council the Netherlands 2007
11. ACIP Recommendations 2012 [ http://www.cdc.gov/vaccines/pubs/ACIP-list. htm ], acces date: 02-04
12. History of the notifications. Van Vliet JA, Tijdschrift voor infectieziekten 2009 4 2 51 60
13. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Jansen AG, Rodenburg GD, van der Ende A, van Alphen L, Veenhoven RH, Spanjaard L, Sanders EA, Hak E, Clin Infect Dis 2009 49 2 23 29 10.1086/600045 19522653
14. Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. De Melker HE, Conyn-van Spaendonck MA, Epidemiol Infect 1998 121 3 637 643 10.1017/S0950268898001587 10030714 (Pubitemid 29023043)
15. Mollema L, de Melker HE, Hahné SJM, van Weert JWM, Berbers GAM, van der Klis FRM, Pienter 2-Project: second research project on the protection against infectious diseases offered by the national immunization program in the Netherlands Bilthoven: National Institute for Public Health and the Environment 2009
16. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. de Melker H, Berbers G, Hahne S, Rumke H, van den Hof S, de Wit A, Boot H, Vaccine 2006 24 18 3946 3952 10.1016/j.vaccine.2006.02.017 16564115
17. Varicella- en herpeszostervirusinfection-chickenpox and shingles. National Coordination Centre for Outbreak Management, B02 Bilthoven: National Coordination Centre for Outbreak Management, Environment NIfPHa, 2005 last revised 2008
18. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Fedson DS, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, Samson SI, Expert Rev Vaccines 2011 10 8 1143 1167 10.1586/erv.11.99 21810065
19. Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits. Jansen AG, Rodenburg GD, de Greeff SC, Hak E, Veenhoven RH, Spanjaard L, Schouls LM, Sanders EA, van der Ende A, Vaccine 2009 27 17 2394 2401 10.1016/j.vaccine.2009.01.127 19428856
20. Nasopharyngeal carriage of Streptococcus pneumoniae and pneumococcal urine antigen test in healthy elderly subjects. Palmu AA, Kaijalainen T, Saukkoriipi A, Leinonen M, Kilpi TM, Scand J Infect Dis 2012 44 46 433 8 22263905
21. Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. de Greeff SC, de Melker HE, van Gageldonk PG, Schellekens JF, van der Klis FR, Mollema L, Mooi FR, Berbers GA, PLoS One 2010 5 12 14183 10.1371/journal.pone.0014183 21152071
22. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. de Melker HE, Versteegh FG, Schellekens JF, Teunis PF, Kretzschmar M, J Infect 2006 53 2 106 113 10.1016/j.jinf.2005.10.020 16352342 (Pubitemid 44028673)
23. Suijkerbuijk A, Lugnér A, van Pelt W, Wallinga J, Verhoef L, de Melker H, de Wit A, Assesing potential introduction of universal and targeted hepatitis A vaccination in the Netherlands Bilthoven: Rijksinstituut voor Volksgezondheid en Millieu 2012
24. Hepatitis A. National Coordination Centre for Outbreak Management, B15 Bilthoven: National Coordination Centre for Outbreak Management, Environment NIfPHa, 2003 last revised 2009
25. Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Harpas R, Ortega-Sanchez IR, Seward JF, MMWR 2008 57 1 30 19052530
26. Plotkin SA, Orenstein WA, Offit PA, Vaccines Philadelphia: Elsevier 5 2008
27. Pertussis. National Coordination Centre for Outbreak Management, A37 Bilthoven, Environment NIfPHa, 2007
28. Update on pertussis and pertussis immunization. Hong JY, Korean J Pediatr 2010 53 5 629 633 10.3345/kjp.2010.53.5.629 21189928
29. An epidemic of pertussis among elderly people in a religious institution in The Netherlands. Mertens PL, Stals FS, Schellekens JF, Houben AW, Huisman J, Eur J Clin Microbiol Infect Dis 1999 18 4 242 247 10.1007/s100960050271 10385011 (Pubitemid 29527968)
30. Perevoscikovs J Fau-Lucenko I, Lucenko I Fau-Magone S, Magone S Fau-Brila A, Brila A Fau-Curikova J, Curikova J, Community-wide outbreak of hepatitis A in Latvia, in 2008. Eurosurveillance 2008 1560 7917 Electronic
31. Increase in hepatitis A cases in the Czech Republic in 2008-an update. Castkova J, Benes C, Euro Surveill 2009 14 3 19091 19161729
32. Hepatitis A outbreak in a Roma village in eastern Slovakia, August-November 2008. Hrivniakova L, Slacikova M, Kolcunova S, Euro Surveill 2009 14 3 19099
33. Assessing potential introduction of universal or targeted hepatitis A vaccination in the Netherlands. Suijkerbuijk AW, Lugner AK, van Pelt W, Wallinga J, Verhoef LP, de Melker HE, de Wit GA, Vaccine 2012 30 35 5199 205 10.1016/j.vaccine.2012.06.014 22721900
34. Genetic variability of hepatitis A virus. Costa-Mattioli M, Di Napoli A, Ferre V, Billaudel S, Perez-Bercoff R, Cristina J, J Gen Virol 2003 84 Pt 12 3191 3201 14645901 (Pubitemid 37540748)
35. Distribution of varicella-zoster virus (VZV) wild-type genotypes in northern and southern Europe: evidence for high conservation of circulating genotypes. Loparev VN, Rubtcova EN, Bostik V, Tzaneva V, Sauerbrei A, Robo A, Sattler-Dornbacher E, Hanovcova I, Stepanova V, Splino M, et al. Virology 2009 383 2 216 225 10.1016/j.virol.2008.10.026 19019403
36. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, Heuvelman KJ, de Greeff SC, Diavatopoulos D, Teunis P, Nagelkerke N, et al. Emerg Infect Dis 2009 15 8 1206 1213 10.3201/eid1508.081511 19751581
37. Influenza- and respiratory syncytial virus-associated mortality and hospitalisations. Jansen AG, Sanders EA, Hoes AW, van Loon AM, Hak E, Eur Respir J 2007 30 6 1158 1166 10.1183/09031936.00034407 17715167 (Pubitemid 351194764)
38. Prevention of herpes zoster and its painful and debilitating complications. Johnson R, McElhaney J, Pedalino B, Levin M, Int J Infect Dis 2007 11 Suppl 2 43 48 18162246
39. Update on vaccine-preventable diseases: are adults in your community adequately protected? Schaffner W, J Fam Pract 2008 57 4 Suppl) 1 11 quiz S12 18655764
40. Immunogenicity and safety of ZOSTAVAX(R) approaching expiry potency in individuals aged >/=50 years. Arnou R, Fiquet A, Thomas S, Sadorge C, Hum Vaccin 2011 7 10 1060 1065 10.4161/hv.7.10.16480 21941091
41. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. Schmader K, Gnann JW Jr, Watson CP, J Infect Dis 2008 197 Suppl 2 207 215 18419399
42. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA, CMAJ 2010 182 16 1731 1736 20921251
43. Acute pain in herpes zoster and its impact on health-related quality of life. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH, Clin Infect Dis 2004 39 3 342 348 10.1086/421942 15307000 (Pubitemid 39050481)
44. Keeping our adult patients healthy and active: the role of vaccines across the lifespan. Schaffner W, Rehm SJ, File TM Jr, Phys Sportsmed 2010 38 4 35 47 21150140
45. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. van Lier A, van Hoek AJ, Opstelten W, Boot HJ, de Melker HE, BMC Health Serv Res 2010 10 237 10.1186/1472-6963-10-237 20707884
46. Time trends in primary-care morbidity, hospitalization and mortality due to pneumonia. van Gageldonk-Lafeber Ab Fau -Bogaerts MAH, Bogaerts Ma Fau -Verheij RA, van der Verheij Ra Fau -Sande MAB, van der Sande MA, Epidemiology and infection 2009 1469 4409 Electronic
47. What is pneumococcal infection and what is the prevalence? Schouls LM, de Greeff SC, Volksgezondheid Toekomst Verkenning (Dutch) Bilthoven: National Institute for Public Health and Environment, Compass NPH, 2010
48. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged ≥65 years in the Netherlands. Rozenbaum MH, Hak E, van der Werf TS, Postma MJ, Clin Ther 2010 32 8 1517 1532 10.1016/j.clinthera.2010.06.016 20728764
49. Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies. de Greeff SC, Lugner AK, van den Heuvel DM, Mooi FR, de Melker HE, Vaccine 2009 27 13 1932 1937 10.1016/j.vaccine.2009.01.106 19368774
50. Morbidity of pertussis in adolescents and adults. De Serres G, Shadmani R, Duval B, Boulianne N, Dery P, Douville Fradet M, Rochette L, Halperin SA, J Infect Dis 2000 182 1 174 179 10.1086/315648 10882595 (Pubitemid 30497802)
51. Haagsma JH, van der Zanden BP, Tariq L, van Pelt W, van Duynhoven YTPH, Havelaar AH, Disease burden and costs of selected foodborne pathogens in the Netherlands, 2006 Bilthoven: National institute for public health and environment 2009
52. Working population is ageing [(http://www.cbs.nl/nl-NL/menu/themas/ arbeid-sociale-zekerheid/publicaties/artikelen/archief/2009/2009-2909-wm.htm)] Acces date: 18-04-2012
53. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Drolet M, Levin MJ, Schmader KE, Johnson R, Oxman MN, Patrick D, Fournier SO, Mansi JA, Brisson M, Vaccine 2012 30 12 2047 2050 10.1016/j.vaccine.2012.01.045 22285632
54. Effectiveness of immune globulins in preventing infectious hepatitis and hepatitis A: a systematic review. Bianco E, De Masi S, Mele A, Jefferson T, Dig Liver Dis 2004 36 12 834 842 10.1016/j.dld.2004.07.014 15646432 (Pubitemid 41070584)
55. Farmaceutisch Kompas, Pneumococcal vaccine Diemen: College voor Zorgverzekeringen 2006
56. FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. CDC, MMWR Morb Mortal Wkly Rep 2011 60 1279 1280 21937974
57. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. N Engl J Med 2005 352 22 2271 2284 10.1056/NEJMoa051016 15930418 (Pubitemid 40740551)
58. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Schmader Ke Fau -Johnson GR, Johnson Gr Fau-Saddier P, Saddier P Fau-Ciarleglio M, Ciarleglio M Fau-Wang WWB, Wang Ww Fau-Zhang JH, Zhang Jh Fau-Chan ISF, Chan Is Fau-Yeh S-S, Yeh Ss Fau -Levin MJ, Levin Mj Fau -Harbecke RM, Harbecke Rm Fau -Oxman MN, et al. Journal of American Geriatrics Society 2010 1532 5415 Electronic
59. Zoster vaccine: current status and future prospects. Oxman MN, Clin Infect Dis 2010 51 2 197 213 10.1086/653605 20550454
60. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Hak E, Grobbee DE, Sanders EA, Verheij TJ, Bolkenbaas M, Huijts SM, Gruber WC, Tansey S, McDonough A, Thoma B, et al. Neth J Med 2008 66 9 378 383 18990781
61. Vaccines for preventing pneumococcal infection in adults. Moberley S, Holden J, Tatham David P, Andrews Ross M, Cochrane Database of Systematic Reviews Chichester, UK: John Wiley & Sons, Ltd 2008
62. If pneumonia is the "old man's friend", should it be prevented by vaccination? An ethical analysis. Zimmerman RK, Vaccine 2005 23 29 3843 3849 10.1016/j.vaccine.2005.01.158 15893623 (Pubitemid 40711193)
63. Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Ward JI, Cherry JD, Chang SJ, Partridge S, Keitel W, Edwards K, Lee M, Treanor J, Greenberg DP, Barenkamp S, et al. Clin Infect Dis 2006 43 2 151 157 10.1086/504803 16779740
64. Efficacy of an acellular pertussis vaccine among adolescents and adults. Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J, Greenberg DP, Keitel W, Barenkamp S, Bernstein DI, et al. N Engl J Med 2005 353 15 1555 1563 10.1056/NEJMoa050824 16221778 (Pubitemid 41434634)
65. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix((R))) in adults 55 years of age and over: A sub-analysis of four trials. Van Damme P, McIntyre P, Grimprel E, Kuriyakose S, Jacquet JM, Hardt K, Messier M, Van Der Meeren O, Vaccine 2011 29 35 5932 5939 10.1016/j.vaccine. 2011.06.049 21718738
66. Duration of immunity against pertussis after natural infection or vaccination. Wendelboe AM, Van Rie A, Salmaso S, Englund JA, Pediatr Infect Dis J 2005 24 5 Suppl 58 61 15876927
67. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. D'Acremont V, Herzog C, Genton B, J Travel Med 2006 13 2 78 83 10.1111/j.1708-8305.2006.00001.x 16553593
68. Hepatitis A vaccines. Nothdurft HD, Expert Rev Vaccines 2008 7 5 535 545 10.1586/14760584.7.5.535 18564009 (Pubitemid 351881338)
69. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Sanford M, Keating GM, Drugs Aging 2010 27 2 159 176 10.2165/10489140-000000000-00000 20104941
70. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged >/=65 years. Schwarz TF, Flamaing J, Rumke HC, Penzes J, Juergens C, Wenz A, Jayawardene D, Giardina P, Emini EA, Gruber WC, et al. Vaccine 2011 29 32 5195 5202 10.1016/j.vaccine.2011.05.031 21619909
71. Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults. Weston WM, Chandrashekar V, Friedland LR, Howe B, Hum Vaccin 2009 5 12 858 866 19838080
72. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Andre F, Van Damme P, Safary A, Banatvala J, Expert Rev Vaccines 2002 1 1 9 23 10.1586/14760584.1.1.9 12908508 (Pubitemid 36686875)
73. Adult immunizations: update on recommendations. Pham H, Geraci SA, Burton MJ, Am J Med 2011 124 8 698 701 10.1016/j.amjmed.2010.07.032 21658665
74. Medicijnkosten [ http://www.medicijnkosten.nl ] Acces date: 12-04-2012
75. A critical literature review of health economic evaluations in pertussis booster vaccination. Millier A, Aballea S, Annemans L, Toumi M, Quilici S, Expert Rev Pharmacoecon Outcomes Res 2012 12 1 71 94 10.1586/erp.11.94 22280198
76. Cost effectiveness of pertussis vaccination in adults. Lee GM, Murphy TV, Lett S, Cortese MM, Kretsinger K, Schauer S, Lieu TA, Am J Prev Med 2007 32 3 186 193 10.1016/j.amepre.2006.10.016 17296470 (Pubitemid 46216742)
77. Immunosenescence: Implications for vaccination programmes in adults. Lang PO, Govind S, Michel JP, Aspinall R, Mitchell WA, Maturitas 2011 68 4 322 330 10.1016/j.maturitas.2011.01.011 21316879
78. National Health Council the Netherlands, Influenza vaccination: revision of the indication The Hague: National Health Council the Netherlands 2007
79. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Civen R, Chaves SS, Jumaan A, Wu H, Mascola L, Gargiullo P, Seward JF, Pediatr Infect Dis J 2009 28 11 954 959 10.1097/INF.0b013e3181a90b16 19536039
80. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Lu PJ, Euler GL, Jumaan AO, Harpaz R, Vaccine 2009 27 6 882 887 10.1016/j.vaccine.2008. 11.077 19071175